TAT 2019: Programme

The 17th edition of the International Congress on Targeted Anticancer Therapies (TAT) will take place in Paris, 25-27 February 2019.

In the TAT 2019 programme, major updates and innovation in the field of cancer treatment using exciting novel targeted agents and immunotherapy will be presented along with new points to consider including the role of microbiome in drug development. The issue of combination in the use of immuno-oncology agents will be largely discussed as well as new immunotherapy approaches and methodological issues. In addition to the usual congress sessions, Workshops at lunch time and “Meet the expert” sessions are planned to allow interactivity among the participants

View the online programme

Learning Objectives 

TAT is the place of early phase clinical trials with new agents aiming at specific targets that may help patient selection. 

Attending TAT 2019 will foster:

  • Learning about new methodologies for a biomarker-selected patient population for early drug development including agnostic approaches
  • Discovery of emerging therapeutic strategies based on new targets or pathways
  • Continuing education in cancer immunotherapy rationale, potential combinations and the methodological challenge of evaluation
  • Interaction and networking in workshop and “Meet the expert”-sessions

Accreditation

ESMO-MORA: The TAT 2019 programme will be submitted for ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.